Chinese biopharmaceutical company Kelun Biotech announced that its phase 3 trial of the antibody-drug conjugate sacituzumab tirumotecan (sac-TMT), in combination with Merck‘s Keytruda (pembrolizumab), has met...
Merck & Co. and Eisai Co., Ltd. announced disappointing results from their late-stage clinical trial investigating the combination of Keytruda, an immunotherapy, and Lenvima, a targeted...
